Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.
暂无分享,去创建一个
Diane Solomon | John Schiller | Allan Hildesheim | Sholom Wacholder | Bernal Cortés | Rolando Herrero | Mark Schiffman | D. Lowy | S. Wacholder | D. Solomon | A. Hildesheim | A. Rodriguez | M. Schiffman | C. Porras | P. González | R. Herrero | C. Bratti | J. Morales | M. Alfaro | J. Schiller | E. Freer | Enrique Freer | Concepción Bratti | Mario Alfaro | Jorge Morales | Ana C Rodríguez | John Schussler | Paula González | Carolina Porras | Silvia Jiménez | Diego Guillen | Jean Cyr | Kerrygrace Morrisey | Yenory Estrada | Lidia Ana Morera | Douglas Lowy | Bernal Cortés | John Schussler | D. Guillén | Jean-Pierre Cyr | Yenory Estrada | L. Morera | Silvia E. Jiménez | Kerrygrace Morrisey | Diego Guillén | Paula González
[1] D. Lowy,et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. , 2007, JAMA.
[2] F. Bray,et al. Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.
[3] L. Mango,et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. , 1997, Revista panamericana de salud publica = Pan American journal of public health.
[4] S. Franceschi,et al. Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide , 2006, International journal of cancer.
[5] Michael Quinn,et al. Chapter 8: Screening for cervical cancer in developing countries. , 2006, Vaccine.
[6] S. Wacholder,et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. , 2008, Journal of the National Cancer Institute.
[7] Jose Jeronimo,et al. Human papillomavirus and cervical cancer , 2007, The Lancet.
[8] H. Lawson,et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[9] X. Castellsagué,et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. , 2008, Vaccine.
[10] M. Plummer,et al. Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica , 2000 .
[11] W. Quint,et al. Technical Advance Novel Short-Fragment PCR Assay for Highly Sensitive Broad-Spectrum Detection of Anogenital Human Papillomaviruses , 1998 .
[12] D M Parkin,et al. International trends in incidence of cervical cancer: II. Squamous‐cell carcinoma , 2000, International journal of cancer.
[13] M. Lehtinen,et al. Introducing human papillomavirus vaccines—questions remain , 2008, Annals medicus.
[14] Diane Solomon,et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. , 2007, American journal of obstetrics and gynecology.
[15] S. Wacholder,et al. Epidemiology of Genital Chlamydia trachomatis Infection Among Young Women in Costa Rica , 2008, Sexually transmitted diseases.
[16] M. Sherman,et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[17] S. Wacholder,et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica , 2001, British Journal of Cancer.
[18] W. Quint,et al. Comparison of the SPF10-LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica , 2007, Journal of Clinical Microbiology.
[19] S Wacholder,et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. , 2000, JAMA.
[20] Guillermo Marshall,et al. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[21] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[22] Henry C Kitchener,et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.
[23] J. Berzofsky,et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. , 2006, Cancer research.
[24] Allan Hildesheim,et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,. , 2004, Revista panamericana de salud publica = Pan American journal of public health.
[25] Wim Quint,et al. Development and Clinical Evaluation of a Highly Sensitive PCR-Reverse Hybridization Line Probe Assay for Detection and Identification of Anogenital Human Papillomavirus , 1999, Journal of Clinical Microbiology.
[26] C. Wheeler,et al. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. , 2005, American journal of clinical pathology.
[27] C. Wheeler,et al. A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.
[28] H. Hollema,et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas , 1996, Journal of clinical microbiology.
[29] K. Straif,et al. Carcinogenicity of human papillomaviruses. , 2005, The Lancet. Oncology.
[30] C. Wheeler,et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.
[31] S. Wacholder,et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.
[32] W. Quint,et al. Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.